Prostate cancer (PCa) is the most commonly diagnosed noncutaneous malignancy and second leading cause of cancer-related deaths in US males.
Clinically, locally confined disease is treated surgically and/or with radiation therapy. Invasive disease, however, must be treated with pharmacological inhibitors of androgen receptor (AR) activity, since disease progression is fundamentally reliant on AR activation. However, despite initially effective treatment options, recurrent castration-resistant PCa (CRPC) often occurs due to aberrant reactivation of AR. Additionally, it is appreciated that many other signaling molecules, such as transcription factors, oncogenes, and tumor suppressors, are often perturbed and significantly contribute to PCa initiation and progression to incurable disease. Understanding the interplay between AR signaling and other signaling networks altered in PCa will advance therapeutic approaches. Overall, comprehension of the molecular composition promoting neoplastic growth and formation of CRPC is paramount for developing durable treatment options.
Written by:
Schrecengost R, Knudsen KE. Are you the author?
Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA; Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Reference: Semin Oncol. 2013 Jun;40(3):244-58.
doi: 10.1053/j.seminoncol.2013.04.001
PubMed Abstract
PMID: 23806491
UroToday.com Prostate Cancer Section
